The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1141-1153

  Wang, Hongjie ^a,b   Vinnikov, Ilya ^c   Shahzad, Khurrum ^a,f   Bock, Fabian ^a,c   Ranjan, Satish ^a   Wolter, Juliane ^a   Kashif, Muhammed ^c   Oh, Jun ^d   Bierhaus, Angelika ^c   Nawroth, Peter ^c   Kirschfink, Michael ^c   Conway, Edward M ^e   Madhusudhan, Thati ^a   Isermann, Berend ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Complement; Diabetic nephropathy; Endothelial dysfunction; Podocyte; Thrombomodulin

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ENOXAPARIN; FONDAPARINUX; GENOMIC DNA; PROTEIN C; THROMBOMODULIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY INJURY; MOLECULAR CLONING; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; KIDNEY GLOMERULUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PODOCYTES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBOMODULIN;

EID: 84871422480     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0460     Document Type: Article

References (43)

1. Stewart JH, McCredie MR, Williams SM. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrol Dial Transplant 2006; 21: 2178-2183.
2. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-1358.
3. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185: 5628-5636.
4. Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011; 412: 1171-1179.
5. Badeanlou L, Furlan-Freguia C, Yang G, et al. Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med 2011; 17: 1490-1497.
6. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
7. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-1144.
8. Saraheimo M, Forsblom C, Hansen TK, et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005; 48: 198-202.
9. Hovind P, Hansen TK, Tarnow L, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005; 54: 1523-1527.
10. Hansen TK, Gall MA, Tarnow L, et al. Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 2006; 166: 2007-2013.
11. Hansen TK, Forsblom C, Saraheimo M, et al. Association between mannosebinding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 2010; 53: 1517-1524.
12. Ostergaard J, Hansen TK, Thiel S, et al. Complement activation and diabetic vascular complications. Clin Chim Acta 2005; 361: 10-19.
13. Acosta J, Hettinga J, Fluckiger R, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450-5455.
14. Qin X, Goldfine A, Krumrei N, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653-2661.
15. Davies CS, Harris CL, Morgan BP. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology 2005; 114: 280-286.
16. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003; 1: 1515-1524.
17. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
18. Gil-Bernabe P, D'Alessandro-Gabazza CN, Toda M, et al. Exogenous activated protein C inhibits the progression of diabetic nephropathy. J Thromb Haemost 2012; 10: 337-346.
19. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-577.
20. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
21. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813-1824.
22. Wang H, Madhusudhan T, He T, et al. Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood 2011; 117: 5231-5242.
23. Lin M, Yiu WH, Wu HJ, et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
24. Harper PA, Robinson JM, Hoover RL, et al. Improved methods for culturing rat glomerular cells. Kidney Int 1984; 26: 875-880.
25. Conway EM, Pollefeyt S, Collen D, et al. The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. Blood 1997; 89: 652-661.
26. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibodyinduced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
27. Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation 2009; 120: 774-784.
28. Hansen TK, Tarnow L, Thiel S, et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53: 1570-1576.
29. Falk RJ, Sisson SP, Dalmasso AP, et al. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987; 9: 121-128.
30. Wehner H, Hohn D, Faix-Schade U, et al. Glomerular changes in mice with spontaneous hereditary diabetes. Lab Invest 1972; 27: 331-340.
31. Mauer SM, Michael AF, Fish AJ, et al. Spontaneous immunoglobulin and complement deposition in glomeruli of diabetic rats. Lab Invest 1972; 27: 488-494.
32. Michels LD, O'Donnell MP, Keane WF. Glomerular hemodynamic and structural correlations in long-term experimental diabetic rats. J Lab Clin Med 1984; 103: 840-847.
33. Ostergaard J, Thiel S, Gadjeva M, et al. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia 2007; 50: 1541-1549.
34. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101: 1983-1991.
35. Wang W, Nagashima M, Schneider M, et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-22947.
36. Campbell WD, Lazoura E, Okada N, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
37. Sumi A, Yamanaka-Hanada N, Bai F, et al. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice. Biol Pharm Bull 2011; 34: 824-830.
38. Zhou W, Marsh JE, Sacks SH. Intrarenal synthesis of complement. Kidney Int 2001; 59: 1227-1235.
39. Accardo-Palumbo A, Triolo G, Colonna-Romano G, et al. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. Diabetologia 2000; 43: 1039-1047.
40. Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. J Atheroscler Thromb 1998; 5: 21-28.
41. Borcea V, Morcos M, Isermann B, et al. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa 1999; 28: 172-180.
42. Rosoklija GB, Dwork AJ, Younger DS, et al. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol 2000; 99: 55-62.
43. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51: 3499-3504.